first-quart robust across board pipelin catalyst remain
thursday april market open report first-quart
financi result exhibit beat top bottom line rais
ep growth guidanc due strong sale key
franchis continu benefit tax reform revenu quarter
billion beat estim billion consensu billion world-wide
humira revenu billion higher estim billion consensu
billion imbruvica revenu record million
estim million consensu million hcv franchis sale
million slightli estim million convincingli consensu
roughli million mavyret continu rapid uptak alreadi reach hcv
market share less three quarter market continu forecast
peak market share mavyret franchis reach equilibrium gilead
bottom line non-gaap ep consensu estim
complet varianc analysi expect consensu actual result
summar exhibit manag issu updat guidanc non-gaap ep
announc plan begin tender offer buy
billion common stock start earli may new non-gaap
ep estim previou estim slightli
guidanc also slightli lower ep estim due slightli
return equiti ttm
biopharmaceut compani major busi franchis autoimmun oncolog virolog
area base north chicago illinoi
pleas refer import disclosur page analyst certif page
william blair affili seek busi compani cover research report
result investor awar firm may conflict interest could affect object
report report intend provid person invest advic opinion recommend
herein take account individu client circumst object need intend
recommend particular secur financi instrument strategi particular client recipi
report must make independ decis regard secur financi instrument mention
share pull back quarter due primarili shortfal rova-t rovalpituzumab tesirin
triniti trial third-lin later small cell lung cancer sclc despit disappoint note rova-t
far dead good number late-stag pipelin catalyst come commerci launch multipl
new franchis label extens expect next month rova-t current phase studi
earlier line sclc data read basket studi combin checkpoint inhibitor
could read key proof-of-concept data next month rest upadacitinib safeti profil repres
singl import catalyst compani opinion believ risankizumab elagolix low
data regulatori risk look forward readout last phase studi select-earli later fulli
assess benefit-risk profil far remain optimist post baricitinib panel held april elagolix expect
approv endometriosi associ pain third quarter bleed due uterin fibroid approv
risankizumab psoriasi consid low risk event upadacitinib rheumatoid arthriti
anticip label expans new exist product expect throughout next year
particular venclexta approv relapse/refractori chronic lymphoblast leukemia cll expect nearest-
term event could drive immedi growth
maintain outperform rate lower fair valu estim share base
lower perform pharma biotech peer group increas oper expens project abbvi
top- bottom-lin compound-annual-growth-rate respect beyond humira
revenu start declin project top- bottom-lin compound-annual-growth-rate respect note project
includ current market product late-stag pipelin candid believ current earlier-stag asset
start contribut growth beyond share pull back recent month due primarili
rova-t triniti trial shortfal under-valued opinion stock trade discount pharma
biotech peer despit fact current repres one highest growth rate pharma biotech
peer group fair valu estim put among top term price-to-earnings multipl believ growth
prospect well strong pipelin deserv premium
first quarter net revenu billion repres growth year ago period growth
sequenti top three product humira sale grew year-over-year imbruvica grew year-over-
year hcv franchis sale increas quarter-over-quart bolster strong mavyret uptak
domin humira franchis persever despit new competit sale maintain double-digit year-over-year growth
consecut quarter first quarter exhibit world-wide year-over-year humira growth
attribut increas unit state increas intern exhibit account
abbvi adjust sale quarter imbruvica revenu grew quarter-over-quart includ
increas sale increas intern profit share expect imbruvica continu domin
second-lin chronic lymphocyt leukemia cll set current hold market well continu
expans frontlin cll recent approv indic margin zone lymphoma mzl chronic graft-versus-
host diseas gvhd hcv franchis sale show continu momentum strong fourth quarter total
million mavyret rapid uptak biggest surpris quarter alreadi reach hcv market share
less three quarter market continu forecast peak market share mavyret franchis
reach equilibrium gilead hcv franchis manag note explos growth first quarter part
attribut treat wareh patient fail regimen mavyret expect growth start flatten
second half
updat estim follow increas sale estim hcv franchis billion
billion reflect continu strong mavyret perform quarter-over-quart basi hcv revenu grew driven
rapid uptak mavyret manag note end first quarter mavyret penetr
hcv market current contract access cover patient impress given short time
market due mavyret simpl algorithm competit profil forecast mavyret achiev
world-wide matur market share gilead hcv franchis three product continu see mavyret major
growth driver revenu contributor beyond reach billion sale also slightli
rais sale estim imbruvica billion billion line guidanc new ep estim
previou estim slightli higher top end guidanc also slightli
lower ep estim due increas oper expens top line
increas sale estim billion billion billion respect
updat pipelin project exhibit lower fair valu estim share
base follow rational continu trade discount peer large-cap biotech
pharma compani comp group come valuat last quarter exhibit updat averag
price-to-earnings multipl comp group valuat purpos take averag time non-gaap ep
estim time estim time estim compar previou averag time
time time respect multipl chosen percentil compar biotech
pharmaceut multipl given year use formula arriv fair valu estim share
compound-annual-growth-rate describ believ gradual share could garner higher-than-averag multipl go
recent failur triniti subsequ sell-off look numer near-term product launch
multibillion-dollar potenti well label expans within key franchis throughout next month
drive top- bottom-lin growth continu support out-performance second quarter top-lin data
pivot triniti rova-t third line sclc fell short expect wipe nearli billion market cap
one day signal us street larg disregard rova-t valuat despit setback continu
believ pipelin numer upcom de-risk catalyst across variou therapeut field set continu
step rova-t rest stemcentrx pipelin rova-t continu evalu two phase
studi meru taho first- second-lin sclc respect preclin rova-t also shown
synerg agent basket studi rova-t opdivo /- yervoy on-going might becom
fruit howev note meru taho read beyond rova-t compani seven
agent acquir stemcentrx pipelin clinic evalu plan file around three ind per year
risankizumab continu schedul like approv launch moder sever psoriasi
follow approv indic next five seven year second quarter compani
submit biolog licens applic bla fda treat patient moder sever psoriasi
use risankizumab within next day compani expect submit regulatori file european
medicin agenc ema indic base four phase pivot trial show impress
durabl skin clearanc believ risankizumab well posit approv moder sever psoriasi
approv addit indic next five seven year estim peak sale
risankizumab billion
upadacitinib remain track first regulatori file second half potenti approv
current forecast upadacitinib launch bring peak sale billion billion
attribut sale ra second quarter expect top-lin result select-earli fifth final
registr trial phase program investig inhibitor upadacitinib rheumatoid
arthriti ra efficaci upadacitinib strong safeti side imbal venou
thromboembol event vte proportion-adjust ratio report upadacitinib arm versu
placebo arm although note overal rate event consist background rate
ra popul recent fda advisori committe adcom vote april market
perform jak inhibitor baricitinib provid valuabl insight imbal
cardiovascular cv event regard regulatori author context novel jak class adcom
panel ultim vote support approv baricitinib ra lower dose test mg daili qd
rais question numer imbal vte event seen across phase trial well lack
suffici patient exposur data correspond safeti efficaci inform lower dose note
upadacitinib demonstr slightli greater efficaci evenli balanc safeti compar baricitinib
upadacitinib studi collect robust patient exposur data test dose believ
provid stronger power mg qd mg qd straightforward analysi result
follow panel discuss believ concern rais baricitinib less issu evalu
upadacitinib applic total upadacitinib data portray stronger risk-benefit profil
potenti posit becom prefer agent class
manag remain confid approv elagolix endometriosi third quarter pdufa date
supplement new drug applic snda elagolix uterin fibroid uf also track
april fda push back pdufa date three month third quarter cite need addit time
review safeti data includ liver function test submit nda base total data packag
manag reiter confid eventu approv elagolix endometriosis-associ pain
new pdufa date addit earlier quarter partner announc posit
top-lin result compani duplic phase trial elagolix uterin fibroid-associ pain
expect support snda file potenti approv guid estim sale
billion uf endometriosi believ valu elagolix probabl underappreci
continu project billion peak sale indic even moder penetr
numer label expans venclexta beyond next label expans compani
inhibitor expect anticip approv venclexta rituxan r/r cll strong
result venclexta gazyva frontlin cll present fourth quarter approv indic
expect next data readout pivot trial venclexta frontlin aml patient anticip
follow snda later year potenti approv pivot studi also on-going
number addit non-hodgkin lymphoma type includ follicular lymphoma dlbcl waldenstrom
macroglobulinemia across indic compani project venclexta see five label expans
venclexta also evalu treatment myelodysplast syndrom could support
risk outperform rate includ earlier-than-project biosimilar entri humira failur
market product fulfil expect failur key pipelin program commerci success polit
risk busi develop risk
humira hcv imbruvica total sg acquir in-process research total oper interest expens net foreign exchang incom expens pre-tax incom tax net net asset separ mileston acquir acquisit relat intang asset impairment- tax reform repatri tax- impact relat tax law change- tax audit settlement- legal reserves- restructuring- chang fair valu conting transact non- dividend per common weight averag share outstand compani report william blair inc incom estimatespreadvarianceq/q growthy/i growthcon estimate humira oper net compani report william blair estimatescurr quarterexhibit inc current quarter varianc analysi dollar billion except ep william blair
compani reportsexhibit inc humira world-wide y/i y/i growth compani report william blair estimatesexhibit inc humira y/i growth y/i growtheu y/i growthww y/i record record record record exclud top record abbvi william blair co estimatesexhibit inc estim product revenu william blair
biotechnolog consult last page report disclosur price factset william blair co estimatesabbvi inc exhibit import disclosur
